Serum B6 vitamers (pyridoxal 5′-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk: two nested case–control studies in Asian populations

Joyce Y. Huang, Lesley M. Butler, Øivind Midttun, Woon Puay Koh, Per M. Ueland, Renwei Wang, Aizhen Jin, Yu Tang Gao, Jian Min Yuan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Vitamin B6 is an important enzymatic cofactor in pathways relevant for the development of pancreatic cancer. In order to evaluate vitamin B6 as a preventive factor for pancreatic cancer, a biomarker approach is needed to overcome the limitations inherent in self-reported dietary information. Methods: To determine whether levels of serum B6 vitamers, including pyridoxal 5′-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (PA), and the PA/(PLP + PL) ratio (PAr), were associated with risk of pancreatic cancer, two nested case–control studies of 187 incident pancreatic cancer cases and 258 individually matched controls were conducted within two prospective cohorts of 81,501 participants in Shanghai, China, and Singapore. PLP, PL, and PA were quantified in pre-diagnostic serum samples. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for potential confounders. Results: The median (5th–95th percentiles) concentrations of serum PLP among control subjects of the Shanghai and Singapore cohorts were 25.7 (10.0–91.7) nmol/L and 58.1 (20.8–563.0) nmol/L, respectively. In pooled analyses, high serum PLP was associated with a reduced risk of pancreatic cancer (P for trend = 0.048); the adjusted odds ratio for the highest category of PLP (>52.4 nmol/L) was 0.46 (95% CI 0.23, 0.92) compared to vitamin B6 deficiency (<20 nmol/L). No associations were found for serum PL, PA, or PAr with pancreatic cancer risk. Conclusions: Higher concentrations of PLP may protect against the development of pancreatic cancer. The protective effect may be more apparent in populations with low concentrations of circulating vitamin B6.

Original languageEnglish (US)
Pages (from-to)1447-1456
Number of pages10
JournalCancer Causes and Control
Volume27
Issue number12
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Pyridoxic Acid
Pyridoxal
Pyridoxal Phosphate
Pancreatic Neoplasms
Vitamin B 6
Serum
Population
Singapore
Odds Ratio
Vitamin B 6 Deficiency
Confidence Intervals
Tumor Biomarkers
China
Logistic Models

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum B6 vitamers (pyridoxal 5′-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk : two nested case–control studies in Asian populations. / Huang, Joyce Y.; Butler, Lesley M.; Midttun, Øivind; Koh, Woon Puay; Ueland, Per M.; Wang, Renwei; Jin, Aizhen; Gao, Yu Tang; Yuan, Jian Min.

In: Cancer Causes and Control, Vol. 27, No. 12, 01.12.2016, p. 1447-1456.

Research output: Contribution to journalArticle

Huang, Joyce Y. ; Butler, Lesley M. ; Midttun, Øivind ; Koh, Woon Puay ; Ueland, Per M. ; Wang, Renwei ; Jin, Aizhen ; Gao, Yu Tang ; Yuan, Jian Min. / Serum B6 vitamers (pyridoxal 5′-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk : two nested case–control studies in Asian populations. In: Cancer Causes and Control. 2016 ; Vol. 27, No. 12. pp. 1447-1456.
@article{cef3c1081ccd4255b3802421f59c829b,
title = "Serum B6 vitamers (pyridoxal 5′-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk: two nested case–control studies in Asian populations",
abstract = "Background: Vitamin B6 is an important enzymatic cofactor in pathways relevant for the development of pancreatic cancer. In order to evaluate vitamin B6 as a preventive factor for pancreatic cancer, a biomarker approach is needed to overcome the limitations inherent in self-reported dietary information. Methods: To determine whether levels of serum B6 vitamers, including pyridoxal 5′-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (PA), and the PA/(PLP + PL) ratio (PAr), were associated with risk of pancreatic cancer, two nested case–control studies of 187 incident pancreatic cancer cases and 258 individually matched controls were conducted within two prospective cohorts of 81,501 participants in Shanghai, China, and Singapore. PLP, PL, and PA were quantified in pre-diagnostic serum samples. Odds ratios and 95{\%} confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for potential confounders. Results: The median (5th–95th percentiles) concentrations of serum PLP among control subjects of the Shanghai and Singapore cohorts were 25.7 (10.0–91.7) nmol/L and 58.1 (20.8–563.0) nmol/L, respectively. In pooled analyses, high serum PLP was associated with a reduced risk of pancreatic cancer (P for trend = 0.048); the adjusted odds ratio for the highest category of PLP (>52.4 nmol/L) was 0.46 (95{\%} CI 0.23, 0.92) compared to vitamin B6 deficiency (<20 nmol/L). No associations were found for serum PL, PA, or PAr with pancreatic cancer risk. Conclusions: Higher concentrations of PLP may protect against the development of pancreatic cancer. The protective effect may be more apparent in populations with low concentrations of circulating vitamin B6.",
author = "Huang, {Joyce Y.} and Butler, {Lesley M.} and {\O}ivind Midttun and Koh, {Woon Puay} and Ueland, {Per M.} and Renwei Wang and Aizhen Jin and Gao, {Yu Tang} and Yuan, {Jian Min}",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s10552-016-0822-6",
language = "English (US)",
volume = "27",
pages = "1447--1456",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "12",

}

TY - JOUR

T1 - Serum B6 vitamers (pyridoxal 5′-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk

T2 - two nested case–control studies in Asian populations

AU - Huang, Joyce Y.

AU - Butler, Lesley M.

AU - Midttun, Øivind

AU - Koh, Woon Puay

AU - Ueland, Per M.

AU - Wang, Renwei

AU - Jin, Aizhen

AU - Gao, Yu Tang

AU - Yuan, Jian Min

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Vitamin B6 is an important enzymatic cofactor in pathways relevant for the development of pancreatic cancer. In order to evaluate vitamin B6 as a preventive factor for pancreatic cancer, a biomarker approach is needed to overcome the limitations inherent in self-reported dietary information. Methods: To determine whether levels of serum B6 vitamers, including pyridoxal 5′-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (PA), and the PA/(PLP + PL) ratio (PAr), were associated with risk of pancreatic cancer, two nested case–control studies of 187 incident pancreatic cancer cases and 258 individually matched controls were conducted within two prospective cohorts of 81,501 participants in Shanghai, China, and Singapore. PLP, PL, and PA were quantified in pre-diagnostic serum samples. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for potential confounders. Results: The median (5th–95th percentiles) concentrations of serum PLP among control subjects of the Shanghai and Singapore cohorts were 25.7 (10.0–91.7) nmol/L and 58.1 (20.8–563.0) nmol/L, respectively. In pooled analyses, high serum PLP was associated with a reduced risk of pancreatic cancer (P for trend = 0.048); the adjusted odds ratio for the highest category of PLP (>52.4 nmol/L) was 0.46 (95% CI 0.23, 0.92) compared to vitamin B6 deficiency (<20 nmol/L). No associations were found for serum PL, PA, or PAr with pancreatic cancer risk. Conclusions: Higher concentrations of PLP may protect against the development of pancreatic cancer. The protective effect may be more apparent in populations with low concentrations of circulating vitamin B6.

AB - Background: Vitamin B6 is an important enzymatic cofactor in pathways relevant for the development of pancreatic cancer. In order to evaluate vitamin B6 as a preventive factor for pancreatic cancer, a biomarker approach is needed to overcome the limitations inherent in self-reported dietary information. Methods: To determine whether levels of serum B6 vitamers, including pyridoxal 5′-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (PA), and the PA/(PLP + PL) ratio (PAr), were associated with risk of pancreatic cancer, two nested case–control studies of 187 incident pancreatic cancer cases and 258 individually matched controls were conducted within two prospective cohorts of 81,501 participants in Shanghai, China, and Singapore. PLP, PL, and PA were quantified in pre-diagnostic serum samples. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for potential confounders. Results: The median (5th–95th percentiles) concentrations of serum PLP among control subjects of the Shanghai and Singapore cohorts were 25.7 (10.0–91.7) nmol/L and 58.1 (20.8–563.0) nmol/L, respectively. In pooled analyses, high serum PLP was associated with a reduced risk of pancreatic cancer (P for trend = 0.048); the adjusted odds ratio for the highest category of PLP (>52.4 nmol/L) was 0.46 (95% CI 0.23, 0.92) compared to vitamin B6 deficiency (<20 nmol/L). No associations were found for serum PL, PA, or PAr with pancreatic cancer risk. Conclusions: Higher concentrations of PLP may protect against the development of pancreatic cancer. The protective effect may be more apparent in populations with low concentrations of circulating vitamin B6.

UR - http://www.scopus.com/inward/record.url?scp=84994460827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994460827&partnerID=8YFLogxK

U2 - 10.1007/s10552-016-0822-6

DO - 10.1007/s10552-016-0822-6

M3 - Article

C2 - 27830400

AN - SCOPUS:84994460827

VL - 27

SP - 1447

EP - 1456

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 12

ER -